Blog

Antonio Passaro: Tagrisso Plus Chemotherapy Improves Survival in EGFR-Mutated Lung Cancer

Antonio Passaro/LinkedIn

Jul 22, 2025, 08:08

Antonio Passaro: Tagrisso Plus Chemotherapy Improves Survival in EGFR-Mutated Lung Cancer

Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology, shared a post on LinkedIn:

“FLAURA2 reinforces, the significant therapeutic shift initiated by MARIPOSA in frontline EGFR mutant Lung Cancer.

The recent announcement from AstraZeneca on the positive OS results of FLAURA2 confirms a clinically meaningful survival advantage with the addition of chemotherapy to osimertinib in first-line EGFR-mutated advanced NSCLC. Although the full data are not yet publicly available, and will be presented shortly by the end of the year, the topline message is already clear: combination therapy is outperforming osimertinib monotherapy in this setting! But this is not a paradigm shift in isolation.

It is a confirmation and reinforcement of what MARIPOSA had already demonstrated: that combination strategies whether biological chemo-free (amivantamab + lazertinib) or chemo-based offer superior efficacy compared to osimertinib alone.

This alignment of two phase 3 studies underscores that we are entering a new era in EGFRm NSCLC, where monotherapy is no longer the optimal choice for many patients, particularly those at higher risk of early progression or resistance.

Now more than ever, the field must focus on:

Early identification of high-risk features (e.g., TP53 co-mutations, extrathoracic disease, high baseline ctDNA).
Dynamic monitoring of response and resistance through liquid biopsy and longitudinal imaging.
Long-term planning beyond median survival, aiming to increase the rate of patients alive at 4 and 5 years.

This is not just about improving short-term outcomes. It’s about raising the tail of the survival curve, extending durability, and rethinking what long-term disease control means in EGFRm NSCLC. FLAURA2 confirms it. MARIPOSA anticipated it. Now it’s time to act on it, with smarter risk-adapted strategies, deeper profiling, and long-term vision balancing efficacy and safety.”

Read Further.

Antonio Passaro: Tagrisso Plus Chemotherapy Improves Survival in EGFR-Mutated Lung Cancer